Dr. Swapnil Vaidya, MD, PHD
Allergy & Immunology (Allergy Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 105
Licensed in Texas since 2011, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy Physician primary
TX license P0805 (first issued 2011; active) -
Allergy & Immunology (Internal Medicine) Physician
TX license P0805 (first issued 2011; active) -
Allergy & Immunology Physician
TX license P0805 (first issued 2011; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Advanced Allergy and Asthma Associates (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 105
- Services billed
- 6,010
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Professional service for preparation and provision of 1 or more antigens | 2,320 | 48 |
| Test for allergy using allergenic extract | 1,728 | 28 |
| Professional service for multiple injections of allergen | 899 | 43 |
| Test for allergy using allergenic extract injected into skin | 196 | 21 |
| Professional service for single injection of allergen | 192 | 13 |
| Established patient office or other outpatient visit, 20-29 minutes | 50 | 40 |
| Test to measure expiratory airflow and volume | 40 | 31 |
| Established patient office or other outpatient visit, 30-39 minutes | 36 | 30 |
| New patient office or other outpatient visit, 30-44 minutes | 23 | 23 |
| New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Fort Worth, TX | 84 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Fort Worth, TX | 29 |
| Azelastine Hcl Other prescribers in Fort Worth, TX | 28 |
| Epinephrine Other prescribers in Fort Worth, TX | 24 |
| Hyqvia (igg/hyaluronidase,recombinant) | 23 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Fort Worth, TX | 20 |
| Prednisone Other prescribers in Fort Worth, TX | 17 |
| Advair Hfa (fluticasone propion/salmeterol) Other prescribers in Fort Worth, TX | 13 |
| Ipratropium Bromide Other prescribers in Fort Worth, TX | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 72 payments worth $1,609 in total to this clinician.
| Genzyme Corporation | $334 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $305 |
| Regeneron Healthcare Solutions, Inc. | $194 |
| Ars Pharmaceuticals Operations, Inc. | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | $111 |
| Biocryst US Sales Co., LLC | $58.18 |
| Pfizer Inc. | $55.94 |
| Phathom Pharmaceuticals, Inc. | $49.88 |
| Food and Beverage | $1,609 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $16,909 in research payments for these studies, mostly to the institutions running them.
- Observation priority e short - lebrikizumab - atopic dermatitis
Eli Lilly and Company - A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis
Arcutis Biotherapeutics, Inc. - Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Eli Lilly and Company · Completed · NCT04392154 - A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06136741
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.